The reaffirmation of an Outperform rating and a $10 price target by a reputable analyst like Francois Brisebois from Oppenheimer is likely to instill confidence among investors and could positively influence Aldeyra Therapeutics' stock price in the short term. Analyst ratings, especially those that are positive, can have a significant impact on investor sentiment and stock prices.